ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jarle Vaage
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, G.
Right arrow Articles by Valen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, G.
Right arrow Articles by Valen, G.
Related Collections
Right arrow Cardiac - physiology
Right arrow Coronary disease
Right arrowRelated Article

Ann Thorac Surg 2001;71:1296-1303
© 2001 The Society of Thoracic Surgeons


Original article: cardiovascular

Preconditioning protects the severely atherosclerotic mouse heart

Guohu Li, MDa, Shinichi Tokuno, MDa, Peeter Tähepôld, MDa, Jarle Vaage, MD, PhDb, Christian Löwbeer, MDc, Guro Valen, MD, PhDa,b

a Crafoord Laboratory of Experimental Surgery, Karolinska Hospital, Stockholm, Sweden
b Department of Thoracic Surgery, Karolinska Hospital, Stockholm, Sweden
c Department of Clinical Chemistry, Huddinge University Hospital, Huddinge, Sweden

Accepted for publication October 18, 2000.

Address reprint requests to Dr Valen, Crafoord Laboratory of Experimental Surgery L6:00, Karolinska Hospital, S-17176 Stockholm, Sweden
e-mail: guro.valen{at}cmm.ki.se


    Abstract
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Background. Coronary atherosclerosis has profound effects on vascular and myocardial biology, and it has been speculated that the atherosclerotic heart does not benefit from ischemic preconditioning.

Methods. To investigate if atherosclerosis would influence the preconditioning response, Apolipoprotein E/low density lipoprotein (LDL) receptor double knockout mice (ApoE/LDLr-/-) were fed an atherogenic diet (21% fat, 0.15% cholesterol) for 6 to 8 months. At that time, extensive atherosclerotic lesions throughout the coronary tree were seen in transverse sections stained with Oil Red-O. Hearts of ApoE/LDLr-/- mice were Langendorff-perfused with 40 minutes of global ischemia and 60 minutes reperfusion, and compared with C57BL/6 controls. Preconditioning with two episodes of 2 minutes of ischemia and 5 minutes reperfusion, or exposing the mice to a hyperoxic environment (O2 > 98%) for 60 minutes before heart perfusion, was performed.

Results. Hearts of mice with coronary atherosclerosis had worse postischemic function, and increased infarct size and troponin T release compared to hearts of C57BL/6 mice. Ischemic preconditioning improved postischemic ventricular function, and reduced myocardial infarct size and troponin T release in both normal and ApoE/LDLr-/- mice. The effects were most pronounced in ApoE/LDLr-/- hearts. Exposure to hyperoxia exerted a similar protection of function and cell viability of ApoE/LDLr-/- mice hearts.

Conclusions. These findings suggest that the severely atherosclerotic heart may be protected by preconditioning induced by ischemia or hyperoxia.


    Introduction
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Ischemic preconditioning is a powerful tool for myocardial protection. However, clinical investigations of ischemic preconditioning attempted during open heart surgery are controversial [1]. Both beneficial effects on myocardial contractility and hemodynamics [2, 3] and no improvement of hemodynamics or cardiac isoenzyme release have been found [46].

One factor which makes man different from experimental animals and may contribute to the controversial results of clinical preconditioning, is the occurrence of coronary atherosclerosis which profoundly influences vascular and myocardial biology. Possibly atherosclerosis is accompanied by myocardial metabolic adaption secondary to chronic or intermittent hypoxia, making it difficult to achieve protection of such hearts [1]. No previous investigation has evaluated preconditioning in the severely atherosclerotic experimental animal, although one factor contributing to atherosclerosis, hypercholesterolemia, has been studied. Pacing-induced preconditioning was attempted in hearts of rats or rabbits fed a high-cholesterol diet (1% to 2% cholesterol) for 8 to 24 weeks. Hypercholesterolemia blocked pacing-induced immediate, but not delayed, protection, and this was reversed by reducing cholesterol to normal in the presence or absence of mild atherosclerotic lesions [79]. However, the importance of coronary atherosclerosis per se, rather than hypercholesterolemia, for the preconditioning response has not been investigated.

With the development of recombinant DNA-technology, new tools for atherosclerosis research are emerging with mice knocked out for or overexpressing specific lipoproteins [10]. One species employed is the mouse double knocked out for Apolipoprotein E and the low density lipoprotein (LDL) receptor (ApoE/LDLr-/-) [10, 11]. The distribution and contents of the atherosclerotic lesions, including in the coronary arteries, are comparable to those of man, and the process is accelerated when the animals are fed an atherogenic diet [10, 11]. Thus, the ApoE/LDLr-/- mouse is suitable as a model to represent the severe atherosclerosis of patients needing revascularization.

The clinical applicability of ischemic preconditioning is also hampered by problems in determining the mechanisms of action, and thus pharmacologically to evoke the protection in patients. While waiting for universal mechanisms of ischemic preconditioning to be determined for pharmacological targeting, we have recently established a clinically acceptable way of inducing the preconditioning response by pretreating rats with hyperoxia (> 98% oxygen) before perfusing their hearts [12]. Hyperoxia induces a systemic low-grade oxidative stress, and profoundly protects the function and necrosis development in hearts subjected to global ischemia [12].

The aim of the present study was twofold: (1) To investigate if ischemic preconditioning would reduce infarct size and improve cardiac function in the isolated hearts of mice with severe atherosclerosis; and (2) To investigate if exposure to a hyperoxic environment might evoke myocardial protection in the severely atherosclerotic mouse heart analogous to that previously observed in rats with healthy coronary vessels.


    Material and methods
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Animals
The study was performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and was approved by the ethics committee for animal research at the Karolinska Institute. Apolipoprotein E/LDL receptor double knockout mice on C57BL/6 background of either sex were purchased from Bomholtgard (Bomholt, Denmark). When the animals were weaned and approximately 6 weeks old, feeding with an atherogenic diet containing 21% fat/0.15% cholesterol commenced (R683, AnalyCen, Linköping, Sweden). After 6 to 8 months on the diet and water ad libitum, the animals were used for experiments after evaluating the extension of coronary atherosclerosis (see below). Male C57BL/6 mice 3 to 4 months old (B&K Universal AB, Sollentuna, Sweden) were employed as control animals.

Isolated heart perfusion
Mice were anesthetized by intraperitoneal injections of midazolam (Dormicum, Hoffman-La Roche, Lausanne, Switzerland, 25 mg/kg) and 1 mg/kg fentanyl, 50 mg/kg fluanisone (Hypnorm, Janssen Pharmaceutica, Beerse, Belgium). Heparin (500 IU/mouse) was injected into the peritoneum. The hearts were rapidly excised, and placed in ice-cold Krebs-Henseleit buffer (NaCl 118.5 mmol/L, NaHCO3 25.0 mmol/L, KCl 4.7 mmol/L, KH2PO4 1.2 mmol/L, MgSO4 7H2O 1.2 mmol/L, glucose H2O 11.1 mmol/L, CaCL2 H2O 1.8 mmol/L). The aorta was secured onto a grooved 20-gauge stainless steel cannula, and transferred to a Langendorff perfusion apparatus. The hearts were retrogradely perfused with gassed (5% CO2, 95% O2) Krebs Henseleit buffer at a constant pressure of 55 mm Hg. The apparatus was water-jacketed to maintain a core temperature of the heart of 37°C. Global ischemia was achieved by clamping the inflow tubing.

Assessment of cardiac performance
A balloon made of polyethylene plastic was inserted into the left ventricle through the left atrium for isovolumetric recordings of left ventricular systolic (LVSP) and end-diastolic (LVEDP) pressures. The volume of the balloon was large enough to be inflated with 30 µL saline without producing a pressure of more than 1 mm Hg. The balloon was coupled to a graded threaded microsyringe (Hugo Sachs Electronik, March-Hugstetten, Germany), and inflated to obtain a LVEDP of 4 to 7 mm Hg during stabilization (approximately 20 µL saline). For recordings of electrocardiogram (ECG), the tips of two thin teflon-insulated platinum wires were scratched and inserted into the apex of the left ventricle and to the right atrium as ECG electrodes, and a metal clip attached to the 20-gauge steel cannula as the reference electrode. The ECG was imported into a computer system (PCLAB, Astra Hässle AB, Mölndal, Sweden), which calculated heart rate (HR) and percentage of arrhythmias. Every 30 seconds, 3 seconds of ECG were registered, and the waves of all beats during the registration were averaged into one QRS-complex. Arrhythmias were evaluated by the computer as all beats with abnormal QRS complexes or irregular R-R intervals. Coronary flow (CF) was continuously measured using a funnel coupled to a force transducer with an automated air valve deflating every 30 seconds, and is presented as µl/min/mg heart. The maximal and negative value of the first derivative of pressure (dP/dt max and negative dP/dt) as well as left ventricular developed pressure (LVDP = LVSP - LVEDP) and rate pressure-product (RPP = HR x LVSP) were calculated by PCLAB.

Experimental protocol
Hearts were allowed to stabilize for 21 minutes. Only hearts with CF between 1.6 and 4.0 ml/min (C57BL/6 1.6 to 3.1, ApoE/LDLr-/- 1.8 to 3.9), HR 280 to 480 beats/min, LVSP greater than 60 mm Hg, and LVEDP 4 to 7 mmHg were included. After stabilization and the interventions listed below, hearts were subjected to 40 minutes of global ischemia and 60 minutes reperfusion.

C57BL/6 mice were randomized into 2 groups:

  1. C57BL/6, group C: After 21 minutes stabilization, hearts were perfused for 14 minutes before ischemia and reperfusion (n = 10).
  2. C57BL/6 with ischemic preconditioning (group IPC): After stabilization, hearts were subjected to two episodes of 2 minutes global ischemia followed by 5 minutes reperfusion before sustained ischemia (n = 10).

ApoE/LDLr-/- mice were divided into 3 groups:

  1. ApoE, group C: 14 minutes control perfusion before ischemia and reperfusion (n = 7).
  2. ApoE, group IPC: The hearts were subjected to the same protocol as C57BL/6, group IPC (n = 7).
  3. ApoE with hyperoxic preconditioning (group HPC): ApoE/LDLr -/- mice were kept in a hyperoxic (>98% O2) environment for 60 minutes immediately before heart perfusion. This gives a PaO2 of more than 200 mm Hg [12]. After stabilization, hearts were perfused for 14 minutes before global ischemia (n = 7).

A corresponding hyperoxic group of C57BL/6 mice are not included in the present study. A shorter period of hyperoxia (30 minutes) gives optimal protection in those mice and, for the simplicity of presentation, the data are not shown.

Measurement of infarct size
After reperfusion for 60 minutes, hearts were immediately perfused with a total volume of 3 ml 10% triphenyl tetrazolium chloride (TTC, Sigma Chemical Co, St. Louis, MO) delivered at 100 cm H2O. The hearts were fixed in 4% formaldehyde for 24 hours, thereafter preserved in 10% sucrose in phosphate-buffered saline (PBS). The hearts were cut manually into 0.8 to 1.0 mm transverse slices. The sections were visualized in a computer imaging system, and infarct size marked and calculated (LEICA Qwin, Leica Imaging Systems Ltd, Cambridge, UK). An unstained epicardial ring appeared in all hearts. After calculating the size of this ring in various experimental groups and finding it constant, independent of intervention, the outer ring was evaluated as an artifact and excluded from the infarct size calculation. The area of unstained (infarcted) myocardium was calculated as the percentage of total ventricular area minus cavities, and the mean value of all sections in one heart was treated as one value and used for statistics.

Measurement of cardiac troponin T
At the end of stabilization and after 30 minutes of reperfusion, 2 ml samples of the coronary effluent were collected in precooled tubes, stabilized with addition of 4% albumin, and rapidly frozen at -80°C until analysis of cardiac troponin T (cTnT). cTnT was measured with the third generation of the TnT test on the Elecsys 2010 immunoassay analyzer (Roche Diagnostics, Mannheim, Germany). The third generation TnT test uses the same monoclonal antibodies (M11.7 and M7) as the second generation test, but is standardized with human recombinant cTnT instead of bovine cTnT (Troponin T STAT package insert, Roche Diagnostics, Mannheim, Germany). cTnT in the coronary effluent was calculated as the amount released per minute [cTnT (ng/ml)] x CF (ml/min) = ng/min. The delta cTnT release was calculated as release after 30 minutes reperfusion minus release at stabilization, and employed for statistical evaluation.

Microscopic analysis of coronary atherosclerosis
The extension of coronary atherosclerosis was evaluated in hearts of mice fed an atherogenic diet for 6, 7, or 8 months (n = 3 of each). Hearts were harvested and fixed in 4% formaldehyde for 24 hours, thereafter kept on 10% sucrose in PBS until they were cryomounted in OCT. Each heart was divided in three to visualize lesions in the aortic root, the middle section, and the apex area of the heart. Consecutive sections (10 µm thick, n = 30 to 50) from each of the three areas were air-dried, dehydrated, and stained with Oil Red-O for 15 minutes. Counter-staining was performed with hematoxylin. After rinsing with water, the slides were mounted with Kaiser’s glycerol gelatin (Merck, Darmstadt, Germany) under coverslips. The Oil Red-O stained cryosections were observed under microscopy.

Statistical analysis
Data are expressed as mean ± standard error of mean. A two-way analysis of variance was used to compare hemodynamic parameters, with a Scheffe’s post hoc test to verify or falsify apparent differences in comparison between the three groups. Comparisons of infarct size and cTnT release were performed by unpaired t test for independent samples. p less than 0.05 was considered significant.


    Results
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
General information and coronary atherosclerosis
The weight of the ApoE/LDLr-/- mice was 44.7 ± 3.2 g, and their hearts weighed 178.5 ± 7.8 mg at the time of the experiments. Male C57BL/6 mice weighed 26.8 ± 0.8 g, and their hearts weighed 104.5 ± 6.6 mg. The ratio between heart weight and body weight was similar between groups (ApoE/LDLr-/- 0.0040, C57BL/6 0.0039).

The atherosclerotic lesions in the hearts of ApoE/LDLr-/- mice after 6 to 8 months on an atherogenic diet were widespread. In the aortic root, advanced fibrofatty lesions were observed, with lipid deposits in the proximal coronary arteries (Fig 1A). The coronary atherosclerosis could be observed distally in all hearts. A representative section showing five Oil Red-O stained branches of coronary arteries in the right ventricle in the middle section of the heart is shown in Figure 1B. Figure 1C illustrates a coronary artery caught longitudinally in the apex region of the heart, where lipid deposits can be observed.



View larger version (82K):
[in this window]
[in a new window]
 
Fig 1. (A) Transverse section of the aortic root of an Apolipoprotein E/LDL receptor double knockout mouse after being fed a diet containing 21% fat and 0.15% cholesterol for 6 months. The section is stained with Oil Red-O and counterstained with hematoxylin. Note the massive fibrofatty lesions of the aortic wall and in the right coronary artery (arrow). (Original magnification, x200.) (B) A representative section from the middle area of the heart after 8 months on the diet. The cavity of the right ventricle with surrounding wall and septum is depicted. Note multiple lipid deposits in branches of coronary vessels (arrows). (Original magnification, x200.) (C) Oil Red-O staining of a section from the apex region of the heart taken from an animal after 6 months on the atherogenic diet shows a coronary artery with lipid deposits caught longitudinally. (Original magnification, x400.)

 
Cardiac function
Left ventricular pressures
LVDP in hearts of C57BL/6 mice was depressed during reperfusion after 40 minutes of global ischemia, and this was attenuated by ischemic preconditioning (Fig 2A). LVDP in hearts of ApoE/LDLr-/- was similar to controls during stabilization, but more depressed than in controls during reperfusion (Fig 2B). Ischemic preconditioning attenuated this depression, as did pretreating the animals with 60 minutes of hyperoxia (Fig 2B).



View larger version (33K):
[in this window]
[in a new window]
 
Fig 2. (A, B) Left ventricular developed pressure (LVDP) in Langendorff-perfused hearts of C57BL/6 and Apolipoprotein E/LDL receptor double knockout mice (ApoE/LDLr-/-) subjected to 40 minutes of global ischemia and 60 minutes reperfusion after two cycles of 2 minutes ischemia and 5 minutes reperfusion (IPC) and compared to ischemic controls (C). Additional atherosclerotic animals were exposed to 60 minutes of hyperoxia (>98% O2) prior to heart isolation and global ischemia (HPC). Values are mean ± standard error of mean of 7 to 10 animals per group. (BIPC = before ischemic preconditioning; BI = before ischemia; * denotes p < 0.00001; # denotes p < 0.003 in comparison of preconditioned versus ischemic control; a denotes p < 0.0002 when comparing C57BL/6 to ApoE/LDLr-/- ischemic controls.) (B, C) Left ventricular end-diastolic pressure (LVEDP) in the same hearts as above. (* denotes p < 0.000001 in comparison between preconditioned and control hearts; b denotes p < 0.00001 when comparing ApoE/LDLr-/- versus C57BL/6 controls.)

 
LVEDP increased during reperfusion of C57BL/6 hearts, and the increase was reduced by ischemic preconditioning (Fig 2C). The ischemia-reperfusion induced increase of LVEDP was higher in hearts of ApoE/LDLr-/- mice, and was attenuated by both ischemic and hyperoxic preconditioning (Fig 2D).

First derivative of pressure
In C57BL/6 hearts, maximum and negative dP/dt were impaired at the start of reperfusion, without being influenced by ischemic preconditioning (Fig 3A). The depression of max dP/dt and increase of neg dP/dt was more apparent in atherosclerotic hearts, and was attenuated by both ischemic and hyperoxic preconditioning (Fig 3B).



View larger version (37K):
[in this window]
[in a new window]
 
Fig 3. (A, B) Maximum positive and negative first derivative of pressure (max dP/dt and n dP/dt) in Langendorff-perfused hearts of C57BL/6 and Apolipoprotein E/LDL receptor double knockout mice (ApoE/LDLr-/-) subjected to 40 minutes global ischemia and 60 minutes reperfusion after two cycles of 2 minutes ischemia and 5 minutes reperfusion (IPC) and compared to ischemic controls (C). Additional atherosclerotic animals were exposed to 60 minutes hyperoxia (>98% O2) prior to heart isolation and global ischemia (HPC). Coronary flow is corrected for differences in heart weight as described in the Material and Methods section. Values are mean ± standard error of mean of 7 to 10 animals per group. (BIPC = before ischemic preconditioning; BI = before ischemia; * denotes p < 0.00001; # denotes p < 0.0002 in comparison of preconditioned versus ischemic controls; d denotes p < 0.003; e denotes p < 0.00001 when comparing C57BL/6 to ApoE/LDLr-/- ischemic controls.) (C, D) Coronary flow (CF) in the hearts shown above. (* Denotes p < 0.00001 in comparison of preconditioned versus ischemic controls; c denotes p < 0.002 when comparing C57BL/6 to ApoE/LDLr-/- ischemic controls.)

 
Coronary flow
CF decreased only slightly during reperfusion of C57BL/6 hearts, and was not influenced by preconditioning (Fig 3C). Hearts of atherosclerotic mice had lower flow per mg heart weight than C57BL/6 hearts both in the control situation and during reperfusion (Fig 3D). Ischemic and hyperoxic preconditioning increased CF during reperfusion of these hearts (Fig 3D).

Heart rate and arrhythmias
There were no intergroup differences of heart rate before interventions. Heart rate tended to increase, then decrease during reperfusion of C57BL/6 control hearts, and was not influenced by ischemic preconditioning. The rate of ApoE/LDLr-/- mice was not different from C57BL/6 mice. Hyperoxic preconditioning did not influence heart rate in ApoE/LDLr-/- mice, whereas ischemic preconditioning reduced it during reperfusion (at the end of reperfusion, 305 ± 32 beats per minute versus 347 ± 22 in controls; p < 0.006).

The frequency of arrhythmias increased during reperfusion of C57BL/6 hearts, and this was modified by ischemic preconditioning (p < 0.004). For instance, after 15 minutes reperfusion, 30 ± 7% of control hearts had arrhythmias, versus 17 ± 5% of preconditioned hearts. Hearts of ApoE/LDLr-/- mice had less arrhythmias than C57BL/6 hearts during reperfusion (15 minutes reperfusion, 7 ± 3%, p < 0.0001). Neither ischemic nor hyperoxic preconditioning influenced the occurrence of arrhythmias in these hearts.

Rate pressure-product
RPP was not significantly different when comparing C57BL/6 groups, when comparing the three ApoE/LDLr-/- groups, or when comparing C57BL/6 to ApoE/LDLr-/-.

Myocardial infarct size
At the end of reperfusion, hearts were stained with TTC, sectioned, and unstained areas were imaged and calculated. In C57BL/6 hearts, approximately 28% of myocardial tissue was calculated as necrotic after 60 minutes reperfusion (Fig 4A).
Fig 4. (A) A representative transverse section of triphenyl tetrazolium chloride stained heart from the groups shown in panel B. (B) Percentage of necrotic tissue after 60 minutes reperfusion of Langendorff-perfused hearts subjected to 40 minutes global ischemia and TTC-stained. The hearts shown are as in the x-axis on 4C: C57BL/6 ischemic control (C, C57); C57BL/6 preconditioned with two cycles of 2 minutes ischemia and 5 minutes reperfusion before sustained ischemia (IPC, C57); ischemic control of an apolipoprotein E/LDL receptor double knockout mouse after 6 months on atherogenic diet (C, ApoE); ischemic preconditioned ApoE (IPC, ApoE); and a heart of ApoE mouse subjected to 60 minutes hyperoxia prior to heart isolation and global ischemia (HPC, ApoE). Values are mean ± standard error of mean of n = 7 to 10 in each group. (* IPC versus C, p < 0.04; # IPC versus C, p < 0.03; § HPC versus C, p < 0.001;
denotes p < 0.00006 when comparing ApoE/LDLr-/- to C57BL/6 ischemic controls.) (C) Release of cardiac troponin T ({Delta}TnT) shown as the difference between release after 30 minutes of reperfusion and release at end of stabilization (mean ± standard error of mean of 7 to 10 animals in each group). (* IPC, C57 versus C, C57, p < 0.05; # IPC, ApoE versus C, ApoE, p < 0.04; § HPC, ApoE versus C, C ApoE, p < 0.03;
denotes p < 0.02 when comparing ApoE/LDLr-/- to C57BL/6 ischemic controls.)

Ischemic preconditioning reduced this area. Infarct size in ApoE/LDLr-/- mice hearts was larger than in C57BL/6 hearts. Both ischemic and hyperoxic preconditioning reduced the amount of necrotic tissue in atherosclerotic hearts (Fig 4A).

Troponin T release
Basal cTnT release was not different between groups. cTnT release into the coronary effluent increased during reperfusion in all hearts. When the increase in release from stabilization to 30 minutes of reperfusion was calculated, ischemic preconditioning reduced cTnT release in C57BL/6 hearts (Fig 4B). Like infarct size, cTnT release from ApoE/LDLr-/- mice was higher than from C57BL/6 mice, and the cTnT release was attenuated by both hyperoxic and ischemic preconditioning (Fig 4B).


    Comment
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
The major findings of the present study were that isolated hearts of animals with severe atherosclerosis had more pronounced dysfunction during reperfusion after global ischemia, and larger infarcts accompanied by higher troponin T release compared to hearts of animals with healthy vessels. Ischemic preconditioning improved postischemic ventricular function, and reduced infarct size and troponin T release from isolated, perfused atherosclerotic and normal mouse hearts. The present investigation did not aim at targeting mechanisms for preconditioning in the mouse heart. This article reports that preconditioning can protect the severely atherosclerotic heart. Interestingly, the protection afforded by preconditioning was more evident in atherosclerotic mice hearts than in controls. Exposure of ApoE/LDLr-/- mice to hyperoxia for 60 minutes prior to excision of the hearts mimicked the beneficial effects of classic ischemic preconditioning. The extent of coronary atherosclerosis was evaluated prior to conducting physiological experiments. At that time, the hearts had advanced fibrous-fatty lesions in the aortic root, and lipid deposits in the vascular wall of main and branch coronary arteries, with lesions distributed throughout the periphery.

Cardiac function of normal and ApoE/LDLr-/- mice was similar during the stabilization period, but during reperfusion, after global ischemia, the atherosclerotic hearts had more depressed left ventricular performance, increased infarct sizes, and increased cTnT release. Studies performed in hearts of rabbits fed a high-cholesterol diet for a much shorter time than that employed here have found cardiac performance deteriorated [13], unchanged [14], or improved [15] during reperfusion. However, the effects of hypercholesterolemia and atherosclerosis are not necessarily comparable. Hypercholesterolemia before induced infarction in rabbits [14, 16] or LDLr-/- mice [17] has increased infarct size compared to control animals.

In the present study, hearts of ApoE/LDLr-/- mice were larger than those of normal mice. This was due to the fact that the whole mouse was bigger due to the atherogenic diet. It may be a limitation of the present study that the mice were not diet and age-matched. When correcting coronary flow for differences in heart weight, coronary flow was reduced to almost half in hearts of ApoE/LDLr-/- mice. This may be due to obstructed or stenotic coronary vessels, or impairment of endothelium-dependent relaxation associated with atherosclerosis [18]. Indeed, in vitro vessel reactivity of ApoE/LDLr-/- mice of the same age and diet as ours was altered, and this appeared partially dependent on nitric oxide [19]. A surprising finding was that hearts of ApoE/LDLr-/- mice had reduced incidence of arrhythmias during reperfusion compared to C57BL/6 mice. We have not found similar references in the literature, and are at the moment at a loss to explain this finding.

In the present study, classic ischemic preconditioning improved cardiac function, and reduced myocardial infarct size and cTnT release after 40 minutes global, normothermic ischemia in both atherosclerotic and normal mouse hearts. Ischemic preconditioning has previously been shown to reduce infarct size and protect the function of murine hearts [20, 21]. In the present study, the clearest protection on both function and cell survival was afforded ApoE/LDLr-/- mice. The most likely explanation is that the ApoE/LDLr-/- mice had larger infarcts and deteriorated cardiac performance, and therefore benefited more from endogenous protection. Clinical studies employing ischemic preconditioning during coronary artery bypass surgery have controversial results, and it has been questioned whether metabolic alterations due to hypercholesterolemia and atherosclerosis make hearts with chronic ischemic disease difficult to precondition [1]. Rapid pacing induced myocardial protection in hearts of rabbits fed high cholesterol for 8 weeks [9], but not in hearts of rats fed high cholesterol for 24 weeks [8]. Although the preconditioning models and degree of hypercholesterolemia/atherosclerosis are different in the previous and present studies, the present study shows that the severely atherosclerotic heart can be preconditioned. The inconsistent protection found in clinical studies is probably due to other reasons, such as preconditioning of patient groups with short surgical procedures where loss of function and necrosis is negligible.

ApoE/LDLr-/- mice were exposed to 60 minutes of hyperoxia before heart isolation and Langendorff-perfusion. This model has been established in rats to induce both immediate and delayed myocardial protection through inducing a systemic oxidative stress evident as increased serum lipid peroxidation products after 60 minutes [12]. In the present study, hyperoxia protected postischemic function, reduced infarct size, and reduced release of cTnT analogous to classic preconditioning. Although the mediators of hyperoxic cardioprotection are not determined, the mechanism of protection is dependent on activation of nuclear factor kappa-B (NF{kappa}B). After 60 minutes hyperoxia, NF{kappa}B is activated in cardiac tissue, and pharmacological inhibition of its activation abolishes the functional effects [22]. Hyperoxia is a mode of myocardial protection which potentially may be of direct clinical applicability, particularly since it protects the function and inhibits infarct development of the atherosclerotic heart.

Although the mechanisms of preconditioning in the mouse heart are largely unknown, we may speculate on a recently discovered factor. Maulik and colleagues [23] found that classic ischemic preconditioning in the rat was dependent on NF{kappa}B, which was activated during preconditioning, and inhibition of this activation abolished the functional effects as described above for hyperoxia in rats [22]. Two NF{kappa}B-regulated genes, inducible nitric oxide synthase and inducible cyclooxygenase, have recently been suggested to mediate delayed preconditioning in studies of knockout animals [24, 25]. However, it remains to be determined whether the mechanisms are analogous in classic preconditioning.


    Acknowledgments
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
This work has been supported by grants from the Swedish Medical Research Council (11235 and 12665), The Swedish Heart-Lung Foundation, the Foundations Fredrik o Ingrid Thuring, Tore Nilsson, ke Wiberg, Ragnhild and Einar Lundströms Memory, and Aga Gas. Guohu Li has been supported by the Wenner-Gren Foundations, while Peeter Tähepôld has received a grant from the Karolinska Institute.


    References
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 

  1. Zeeuw S., van den Doel M., Duncker D.J., Verdouw P.D. New insights into cardioprotection by ischemic preconditioning and other forms of stress. Ann N Y Acad Sci 1999;874:178-191.[Medline]
  2. Lu E.X., Chen S.X., Yuan M.D., et al. Preconditioning improves myocardial preservation in patients undergoing open heart operation. Ann Thorac Surg 1997;64:1320-1324.[Abstract/Free Full Text]
  3. Illes R.W., Swoyer K.D. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent blood cardioplegia. Ann Thorac Surg 1998;65:752-753.
  4. Cremer J., Steinhoff G., Karck M., et al. Ischemic preconditioning prior to myocardial protection with cold blood cardioplegia in coronary surgery. Eur J Cardiothorac Surg 1997;12:753-758.[Abstract]
  5. Kaukoranta PK, Lepojarvi MP, Ylitalo KV, Kiviuoma KT, Peuhkurinen KJ. Normothermic retrograde cardioplegia with or without preceding ischemic preconditioning. Ann Thorac Surg 1997;63:1268–14.
  6. Malkowski M.J., Kramer C.M., Parvizi S.T., et al. Transient ischemia does not limit subsequent regional dysfunction in humans: a transesophageal echocardiographic study during minimally invasive coronary artery bypass surgery. J Am Coll Cardiol 1998;31:1035-1039.[Abstract/Free Full Text]
  7. Szilvassy Z., Ferdinandy P., Szilvassy J., et al. The loss of pacing-induced preconditioning in atherosclerotic rabbits: role of hypercholesterolemia. J Mol Cell Cardiol 1995;27:2559-2569.[Medline]
  8. Ferdinandy P., Szilvassy Z., Horvath L.I., et al. Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 1997;29:3321-3333.[Medline]
  9. Szekeres L., Szilvassy Z., Ferdinandy P., Nagy I., Karcsu S., Csati S. Delayed cardiac protection against harmful consequences of stress can be induced in experimental atherosclerosis in rabbits. J Mol Cell Cardiol 1997;29:1977-1983.[Medline]
  10. Brestow J.L., Pulmp A., Dammerman M. New mouse models of lipoprotein disorders and atherosclerosis. In: Fuster V., Ross R., Topol E.J., eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, 1996:363-378.
  11. Tangirala R.K., Rubin E.M., Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1996;36:2320-2328.[Abstract]
  12. Tähepôld P., Valen G., Starkopf J., Karaine C., Zilmer M., Vaage J. Pretreating rats with hyperoxia attenuates ischemia-reperfusion injury of the heart. Life Sci 2001;68:1629-1640.[Medline]
  13. Tilton R.G., Cole P.A., Zions J.D., et al. Increased ischemia-reperfusion injury to the heart associated with short-term, diet-induced hypercholesterolemia in rabbits. Circ Res 1987;60:551-559.[Abstract/Free Full Text]
  14. Hoshida S., Yamashita N., Igarashi J., Aoki K., Kuzuya T., Hori M. Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 1997;17:2801-2807.[Abstract/Free Full Text]
  15. Le Grand B., Vie B., Faure P., Degryse A.D., Mouillard P., John G.W. Increased resistance to ischemic injury in the isolated perfused atherosclerotic heart of the cholesterol-fed rabbit. Cardiovasc Res 1995;30:689-696.[Medline]
  16. Golino P., Maroko P.R., Carew T.E. The effects of acute hypercholesterolemia on myocardial infarct size and no-reflow phenomenon during coronary artery occlusion-reperfusion. Circulation 1987;75:292-298.[Abstract/Free Full Text]
  17. Mori N., Horie Y., Gerritsen M.E., Granger D.N. Ischemia-reperfusion induced microvascular responses in LDL-receptor -/- mice. Am J Physiol 1999;276:H1647-H1654.
  18. Oemar B.S., Tschudi M.R., Godoy N., Brovkovich V., Malinski T., Luscher T.F. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998;97:2494-2498.[Abstract/Free Full Text]
  19. Jiang J., Thoren P., Caligiuri G., Hansson G.K., Pernow J. Enhanced phenylephrine-induced rhythmic activity in the atherosclerotic mouse aorta via an increase in opening of Kca channels: relation to Kv channels and nitric oxide. Br J Pharmacol 1999;128:637-646.[Medline]
  20. Xi L., Hess M.L., Kukreja R.C. Ischemic preconditioning in isolated perfused mouse heart: reduction in infarct size without improvement of post-ischemic ventricular function. Mol Cell Biochem 1998;186:69-77.[Medline]
  21. Sumeray M.S., Yellon D.M. Ischaemic preconditioning reduces infarct size following global ischaemia in the murine myocardium. Basic Res Cardiol 1998;93:384-390.[Medline]
  22. Tähepôld P., Starkopf J., Dumitrescu A., Vaage J., Valen G. Hyperoxia protects the postischaemic heart through NF{kappa}B-activation. J Mol Cell Cardiol 2000;32:A20.
  23. Maulik N., Sato M., Price B.D., Das D.K. An essential role of NF{kappa}B in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 1998;429:365-369.[Medline]
  24. Shinmura K., Tang X.L., Wang Y., et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci 2000;97:10197-10202.[Abstract/Free Full Text]
  25. Guo Y., Jones W.K., Xuan Y.-T., et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci 1999;96:11507-11512.[Abstract/Free Full Text]

Related Article

Invited commentary

Ann. Thorac. Surg. 71: 1303-1304. [Full Text]



This article has been cited by other articles:


Home page
Toxicol PatholHome page
E. Golomb, A. Nyska, and H. Schwalb
Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance
Toxicol Pathol, August 1, 2009; 37(5): 572 - 593.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and J. P. Headrick
Clinical cardioprotection and the value of conditioning responses
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Ferdinandy, R. Schulz, and G. F. Baxter
Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Willems, M. E. Reichelt, J. G. Molina, C.-X. Sun, J. L. Chunn, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick
Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts
Cardiovasc Res, July 1, 2006; 71(1): 79 - 87.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Ramzy, V. Rao, and R. D. Weisel
Clinical applicability of preconditioning and postconditioning: The cardiothoracic surgeons's view
Cardiovasc Res, May 1, 2006; 70(2): 174 - 180.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Giricz, M. M. Lalu, C. Csonka, P. Bencsik, R. Schulz, and P. Ferdinandy
Hyperlipidemia Attenuates the Infarct Size-Limiting Effect of Ischemic Preconditioning: Role of Matrix Metalloproteinase-2 Inhibition
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 154 - 161.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Dworschak, L. V. d'Uscio, D. Breukelmann, and J. D. Hannon
Increased tolerance to hypoxic metabolic inhibition and reoxygenation of cardiomyocytes from apolipoprotein E-deficient mice
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H160 - H167.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Vaage and G. Valen
Preconditioning and cardiac surgery
Ann. Thorac. Surg., February 1, 2003; 75(2): S709 - 714.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res, August 15, 2002; 55(3): 526 - 533.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
P. Tahepold, A. Ruusalepp, G. Li, J. Vaage, J. Starkopf, and G. Valen
Cardioprotection by breathing hyperoxic gas--relation to oxygen concentration and exposure time in rats and mice
Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 987 - 994.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Tokuno, K. Hinokiyama, K. Tokuno, C. Lowbeer, L.-O. Hansson, and G. Valen
Spontaneous Ischemic Events in the Brain and Heart Adapt the Hearts of Severely Atherosclerotic Mice to Ischemia
Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 995 - 1001.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jarle Vaage
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, G.
Right arrow Articles by Valen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, G.
Right arrow Articles by Valen, G.
Related Collections
Right arrow Cardiac - physiology
Right arrow Coronary disease
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS